| Immune-related gastritis: An orphan immune-related adverse event. T Etan, SS Shachar, I Wolf, Y Leshem Journal of Clinical Oncology 42 (16_suppl), e24138-e24138, 2024 | | 2024 |
| Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant±atezolizumab and abemaciclib triplet treatment in … KH Jung, SA Im, D Yardley, S Hurvitz, KS Lee, A Sonnenblick, S Shachar, ... Cancer Research 84 (9_Supplement), PS12-08-PS12-08, 2024 | | 2024 |
| Abstract PO1-11-02: Reporting of Post-protocol Therapies in Metastatic Breast Cancer Registration Clinical Trials: A Systematic Review S Shachar, Y Korzets, D Shepshelovich, N Zlotchover, E Amir, A Tibau, ... Cancer Research 84 (9_Supplement), PO1-11-02-PO1-11-02, 2024 | | 2024 |
| Body composition measures as a determinant of Alpelisib related toxicity E Shachar, A Raphael, U Katz, R Kessner, SS Shachar Breast cancer research and treatment, 1-8, 2024 | | 2024 |
| Improved Chemosensitivity Prediction for HR+ HER2-Breast Cancer Patients with MammaPrint High2 risk group in the FLEX Trial J O’Shaughnessy, A Sonnenblick, SS Shachar, S Kümmel, LA Fischer, ... European Journal of Cancer 200, 2024 | | 2024 |
| Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review SS Shachar, Y Korzets, D Shepshelovich, N Zlothover, E Amir, A Tibau, ... Cancer Treatment Reviews, 102666, 2023 | | 2023 |
| Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors D Feldman, LA Sinberger, M Salmon-Divon, J Ben-Dror, SS Shachar, ... BMC cancer 23 (1), 1031, 2023 | 1 | 2023 |
| Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry SS Shachar, M Leviov, R Yerushalmi, K Drumea, M Tokar, ... NPJ Breast Cancer 9 (1), 79, 2023 | 1 | 2023 |
| Body composition measures as predictors of toxicity in patients with metastatic breast cancer receiving PARP inhibitors. T Etan, R Kessner, S Peleg Hasson, A Raphael, A Sonnenblick, ... Journal of Clinical Oncology 41 (16_suppl), e13010-e13010, 2023 | | 2023 |
| Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer KA Nyrop, J Monaco, S Vohra, AM Deal, WA Wood, SS Shachar, EC Dees, ... Supportive Care in Cancer 31 (3), 196, 2023 | 5* | 2023 |
| Physical activity intervention in patients with metastatic breast cancer during active treatment: quality of life and function SS Shachar, H Heiling, HB Muss, D Meghan, CW Wagoner, AM Deal, ... The Oncologist 28 (1), 84-e70, 2023 | 3 | 2023 |
| The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer B Waissengrin, T Zahavi, M Salmon-Divon, A Goldberg, I Wolf, T Rubinek, ... ESMO open 7 (6), 100648, 2022 | 2 | 2022 |
| The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study SS Shachar, G Bar-Sela, A Peer, MT Moskovitz, A Bareket-Samish, ... Journal of Geriatric Oncology 13 (8), 1203-1207, 2022 | 4 | 2022 |
| Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment A Raphael, M Salmon-Divon, J Epstein, T Zahavi, A Sonnenblick, ... Genes 13 (10), 1763, 2022 | 1 | 2022 |
| Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit … SS Shachar, M Leviov, R Yerushalmi, K Drumea, M Tokar, ... Journal of Clinical Oncology 40 (16_suppl), 565-565, 2022 | | 2022 |
| Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews S Lieberman, R Chen-Shtoyerman, Z Levi, S Shkedi-Rafid, S Zuckerman, ... Breast Cancer Research and Treatment 193 (1), 217-224, 2022 | 3 | 2022 |
| TAILORED APPROACH TO THE GERIATRIC PATIENT WITH CANCER O Barak Harefuah 161 (4), 228-232, 2022 | | 2022 |
| Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry SS Shachar, M Leviov, R Yerushalmi, K Drumea, M Tokar, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract P5-13-19: Sarcopenia and skeletal muscle density as predictors of toxicity in patients with metastatic breast cancer receiving alpelisib A Raphael, R Kessner, R Raphael, A Sonnenblick, SS Shachar Cancer Research 82 (4_Supplement), P5-13-19-P5-13-19, 2022 | | 2022 |
| Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS … SS Shachar, M Leviov, R Yerushalmi, K Drumea, M Tokar, ... Cancer Research 82 (4_Supplement), P1-08-14-P1-08-14, 2022 | | 2022 |
